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Abstract
The myogenic response refers to the intrinsic ability of arteries to constrict to elevated
pressure, developing “tone”. The underlying mechanism has yet to be elucidated but
recent evidence suggests that the angiotensin II type 1 receptor (AT1R) is a key
mechanosensor, linking intravascular pressure to tone development. One intriguing
aspect of this receptor is its ability to activate NADPH oxidase (Nox), an enzyme
responsible for the production of reactive oxygen species (ROS). The goal of this study
was to ascertain the role of Nox in myogenic tone development. Isolated rat cerebral
arteries were mounted in a myograph, pressurized to 60mmHg and diameter measured
prior to and following the application of apocynin (a general Nox inhibitor) or ML-171 (a
Nox1 specific inhibitor). Pressure-induced constriction was attenuated by apocynin or
ML-171 in a concentration dependent manner. This response to ML-171 was attenuated
in the presence of paxilline (1 µM) or Ni2+ (50 µM), inhibitors of the large-conductance
Ca2+-activated potassium (BKCa) channel and the T-type Ca2+ channel CaV3.2,
respectively. Control experiments showed no discernable role for Nox2. Subsequent
immunohistochemistry confirmed the presence of CaV3.2 and Nox1 in isolated smooth
muscle cells, and proximity ligation assay showed the two proteins co-localized within
40nm in the cell membrane. These findings indicate rat arterial Nox1 may regulate the
myogenic response by moderating a key negative feedback pathway linked to CaV3.2.
This work sheds new light on mechanosensation and how unique signaling proteins
impact the ability of resistance arteries to respond to intravascular pressure.
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1 Introduction
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The cardiovascular system is comprised of a muscular pump and a network of arteries,
veins, and capillaries which transport blood throughout the body. The major types of
arteries include larger conduit vessels such as the aorta, and smaller resistance vessels,
which include the vascular beds that permeate the organs. Larger vessels are not
considered to be able to dynamically control blood flow, while the resistance arteries are
known to respond to a variety of stimuli including blood flow, tissue metabolism, and
intraluminal pressure (1-4) to actively change diameter in order to regulate the magnitude
and distribution of blood flow to the organs. This process is controlled by arterial smooth
muscle contraction, which in turn is governed by the phosphorylation state of the myosin
light chain 20 (LC20) via the opposing activities of myosin light chain kinase (MLCK)
and myosin light chain phosphatase (MLCP) (5)

1.1 The Smooth Muscle Cell
Arteries are comprised of two main cell types; endothelial and smooth muscle. The
innermost layer of the artery is made of a single layer of endothelial cells arranged
longitudinally along the vessel. Outside this are ~1-3 layers of smooth muscle cells
wrapped circumferentially around the vessel (6,7). The two cell types are separated by an
internal elastic lamina. Smooth muscle cells have an elongated structure with tapered
ends and a single nucleus. They are comprised of two types of fibres: the thick filament
myosin, and the thin filament actin. The filaments run parallel to one another throughout
the cell and are anchored at sites termed focal adhesions, which also contain membranespanning proteins known as integrins (5,8). Smooth muscle type II myosin is the specific
myosin isoform accepted to be responsible for force generation in vascular smooth
muscle cells (5). Each myosin molecule consists of two myosin heavy chain (MHC)
amino acid sequences coiled around one another in a double-helix to form a “tail” region
(Figure 1A). Globular enzymatic heads containing actin binding domains are found at the
N-terminus of the sequences. They are connected to the tail regions by a neck region,
which consists of a 20-kilodalton (kDa) regulatory light chain (LC20) and a 17-kDa
essential light chain (5) (Figure 1A).
Actin is the most abundant protein in smooth muscle. It is made up of individual 42kilodalton monomers which can exist as single units termed globular (G) actin, or as
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polymers made of multiple subunits forming filamentous (F) actin (5,8,9). Actin
filaments are anchored at the cell membrane at focal adhesions, and to one another in the
cytosol at dense bodies (8). Muscle contraction occurs due to the interaction of actin
filaments with myosin, a process regulated by the reversible phosphorylation of myosin
LC20 at the serine 19 (S-19) site. Phosphorylated LC20 (p-LC20) allows actin to activate
MgATPase to use energy from adenosine triphosphate (ATP) to bind the myosin head
domain to actin (5). There is a subsequent movement of the myosin heads, termed a
“power stroke”, and the actin filaments slide toward the focal adhesions, which results in
the shortening of muscle fibres, and ultimately muscle contraction (5,8,9). The
phosphorylation of LC20 is therefore critical in muscle contraction and is regulated by
the opposing activities of MLCK and MLCP (5).
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Figure 1: Diagrams of vascular smooth muscle myosin II, MLCK, and MLCP (A):
Diagram of vascular smooth muscle myosin II containing two catalytic heads containing
actin and ATP binding regions connected to two intertwined myosin heavy chain tails.
The neck region connects the heads and tails and contains an essential light chain and a
regulatory light chain which is the site of phosphorylation required for contraction. (B):
Myosin light chain kinase is an elongated protein with an N-terminal actin binding region
and a C-terminal myosin binding region. A regulatory domain consists of a
pseudosubstrate and (Ca2+)4CaM binding site which unfolds the pseudosubtrate, allowing
the adjacent catalytic site to phosphorylate LC20. (C) Myosin light-chain phosphatase is
an elongated protein containing N-terminal PP1c-δ phosphatase which binds to the
MYPT1 subunit via an RVxF when the protein is active. Adjacent ankyrin repeats are
thought to facilitate the interaction among proteins. MYPT1 activity is modulated via two
phosphorylation sites; threonine (T) 697 and T855. The function of the C-terminal M20
subunit is not known (5).
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1.2 Myosin Light-Chain Kinase
Smooth muscle MLCK is a 125-kDa elongated protein. It consists of an N-terminus actin
binding domain, a coiled PEVK repeat, three immunoglobulin (Ig) domains, and a
fibronectin (Fn3) and C-terminal catalytic, regulatory, and calmodulin (CaM) binding
domains (5) (Figure 1B). Also near the C-terminus is the autoinhibitory pseudosubstrate,
which is folded over the catalytic domain when MLCK is in its inactive state, preventing
access to myosin LC20 (5). Activation of MLCK requires the entry of calcium into the
cytosol, which occurs through voltage gated L-type Ca channels in smooth muscle (4)
(Figure 1B). The intracellular calcium binds to the protein CaM, creating a (Ca2+)4CaM
complex which unfolds the autoinhibitory substrate exposing the catalytic domain. This
allows the catalytic domain to phosphorylate LC20 via activity of phosphotransferase.
Only one of two myosin heads requires phosphorylation, and subsequently is bound to
actin, forming an actin-myosin crossbridge. The myosin head can then move pulling actin
along with it in a “power stroke” resulting in the shortening of muscle fibres, leading to
vessel constriction (5).

1.3 Myosin Light-Chain Phosphatase
Smooth muscle MLCP consists of three major domains; a ~38 kDa catalytic subunit
protein phosphatase 1c-delta (PP1c-δ), a ~110-130 kDa myosin-targeting subunit
(MYPT1), and a ~20 kDa subunit of unknown function (Figure 1C). Its well-established
role is to counterbalance MLCK activity and attenuate constriction by dephosphorylating
LC20 (5, 12). This is achieved via activity of the PP1c-δ phosphatase, while the MYPT1
subunit confers specificity of PP1c-δ to LC20 (5, 12). Regulation of the MYPT1 subunit
is of particular interest due to its essential role of targeting of LC20 for
dephosphorylation. A well-established mechanism of MYPT1 regulation is via
phosphorylation at its threonine 855 (T855) or T697 sites, which prevents MYPT1 from
targeting PP1c-δ to p-LC20 thereby allowing sustained contraction. Studies have shown
phosphorylation of MYPT1 at either its T855 or T697 site have increased smooth muscle
contraction (5, 12). This process is governed through RhoA activation in response to a
contractile stimulus. RhoA subsequently activates Rho kinase (ROK) which is
responsible for MYPT1 phosphorylation. The regulation of vascular smooth muscle
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contraction is required in resistance vessels in order to tightly regulate the magnitude and
distribution of blood flow to the organs. It can be viewed as regulation of the opposing
activities of MLCK and MLCP, but both these processes require an upstream stimulus in
order for activation. Several such stimuli exist, including blood flow, tissue metabolism,
(1-4) and intravascular pressure.

1.4 The Myogenic Response
Over a century ago, Bayliss first surmised that arteries could respond to a fluctuating
change in blood pressure. The so-called “myogenic response” has been widely observed
and is prominent in the cerebral vasculature where constant perfusion must be maintained
over a range of blood pressures (13). It is critical, therefore, that the mechanisms that
tightly regulate tone are understood, as they may be useful for developing therapeutic
targets. The work of Knot & Nelson established that voltage-gated long lasting, or Ltype, calcium channels play a critical role in the myogenic response (4). Intravascular
pressure activates mechanosensitive cation channels, resulting in depolarization which in
turn increases the activity of L-type channels and provides the intracellular calcium
required for vessel constriction. This response is typically assessed with pressure
myography, a technique in which arterial segments are isolated, cannulated at each end
and attached to a pressure pump to control intraluminal pressure. The vessel is bathed in
circulating physiological salt solution and its diameter measured using a microscope and
automated edge detection software.
Classically, pressure-induced changes in arterial tone have been ascribed to a three-step
process. First, a membrane bound mechanosensor will sense pressure, leading to the
activation of a signalling pathway which activates downstream targets that ultimately
result in tone development. The primary signalling mechanisms that regulate myogenic
tone involve regulating the phosphorylation of LC20 either through activation of MLCK
or inhibition of MLCP (5). Some studies suggest that pressure activates mechanosensitive
non-selective cation channels, namely the transient receptor potential (TRP) channels (5,
8, 14), whose activity depolarizes the cell, increasing activity of L-type Ca2+ channels.
The resulting influx of Ca2+ results in CaM binding and subsequent activation of MLCK,
which acts to phosphorylate LC20 (Figure 1). Additionally, intravascular pressure is
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thought to activate RhoA GTP, resulting in ROK-induced phosphorylation of the MYPT1
subunit, which inhibits MLCP activity (5, 15-17). Recent studies have also suggested that
cytoskeletal dynamics (i.e. the conversion of globular (G) to filamentous (F) actin), are
involved in tone regulation (9, 19, 20).
One question of great interest is the identity of the receptor or sensor that activates
downstream targets inducing myogenic constriction. Two of the main candidates include
integrins and G-protein coupled receptors (8, 21-25) however there is no general
agreement as to which one regulates myogenic response. Integrins are membrane
spanning proteins found at focal adhesions which link the actin cytoskeleton to the
extracellular matrix, and thereby transduce force (8, 26). Integrin specific blockade has
been shown to attenuate tone in pressurized vessels (26). Finally, the candidate that has
been more recently investigated is the family of G-protein coupled receptors (21). Recent
evidence suggests that in addition to acting through classic G-protein signalling cascades,
these receptors can also act as mechanosensors to trigger myogenic constriction (21-23);
this formed the basis of the present study. Specifically, recent findings suggest that the
angiotensin type one receptor (AT1R), a classic Gq coupled protein receptor may be
mechanosensitive and induce constriction (21-23).
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Figure 2: Current understanding of the mechanisms of smooth muscle constriction
in the myogenic response. An unknown plasma membrane sensor activates downstream
signalling pathways, resulting in increased activity of MLCK or inhibition of MLCP,
both of which result in enhanced phosphorylation of MLC20 leading to constriction. The
polymerization of actin has also been suggested to enhance constriction (9, 19, 20).
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1.5 G-protein Coupled Receptors (GPCRs)
GPCRs are the largest family of membrane bound proteins and regulate a wide variety of
physiological functions. These proteins generally consist of seven segment membranespanning receptors bound to a cytosolic G-protein. Broadly speaking, they are activated
by a ligand binding to a binding pocket on the receptor, causing a conformational change
which subsequently activates the G-protein which can then signal further downstream
targets (27). GPCRs are divided into five families: rhodopsin (A), secretin (B), glutamate
(C), adhesion (D), and frizzled/taste (E) (28, 29). These are further divided into multiple
subfamilies based on differences in G-protein subtypes and signalling pathways. Recent
work has suggested that GPCRs, in particular the Angiotensin II type-1 receptor (AT1R)
of the rhodopsin family (29) can sense intravascular pressure, initiating downstream
signalling pathways resulting in constriction (21-23). Angiotensin II (Ang II) is a wellestablished vasoconstrictor that acts with the AT1R in a classic G-protein coupled
receptor mechanism (30, 31). Binding of AngII to the AT1R activates Phospholipase C
(PLC), producing Inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 causes
the release of Ca2+ from the sarcoplasmic reticulum (SR) whereas DAG will induce
arterial depolarization. Both events will increase cytosolic [Ca2+], subsequently
mobilizing calmodulin. The Ca2+-calmodulin complex then binds to and activates MLCK
resulting in LC20 phosphorylation and constriction (30- 32). AT1R is also known to
induce contraction by increasing RhoA activity, which in turn increases ROK-induced
phosphorylation of the MYPT1 subunit of MLCP, thereby reducing its ability to
dephosphorylate LC20 (31, 33). The AT1R has other downstream targets in vascular
smooth muscle which may play a role in the myogenic response. Of particular interest is
the reactive oxygen species (ROS) generating enzyme, termed the nicotinamide adenine
dinucleotide phosphatase (NADPH) oxidase (Nox) (32).

1.6 NADPH Oxidase
In addition to the well-known agonist induced constriction pathway, AT1R activation has
also been shown to stimulate the reduced Nox enzyme in cerebral vasculature (32),
whose function is to form reactive oxygen species (ROS) via the transfer of electrons
from NADPH to oxygen molecules. The Nox family of enzymes consists of seven
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isoforms: Nox1-5, dual oxidase (DUOX) 1, and DUOX 2. Nox1, 2, 4, and 5 expression
has been confirmed in the cerebral vasculature (34). Upon activation, a catalytic subunit
transfers electrons in succession from the NADPH substrate to flavin adenine
dinucleotide (FAD), and then to two iron atoms located within its membrane-bound
subunit, and finally to extracellular oxygen, forming the superoxide anion O2- (32, 34-36)
(Figure 3). The superoxide anion is the parent molecule that can form other ROS (32, 3436). In the cerebral vasculature, O2- can react with superoxide dismutase (SOD) to form
hydrogen peroxide (H2O2), or with endothelial nitric oxide (NO) to prevent its relaxing
effect and instead produce ONOO-, a highly reactive compound (34-36).
The first isoform to be discovered was Nox2, also called gp91phox, (phagocyte oxidase)
as it was originally found in phagocytes (35, 36). Nox2 is a catalytic subunit comprised
of six transmembrane α-helices bound to the subunit p22phox to form an inactive enzyme
complex at the cell membrane. The Nox2 subunit binds 2 heme molecules containing iron
and one FAD molecule, a cofactor of NAPDH. The G-protein Rac is also bound to the
catalytic subunit, and is believed to be essential in Nox activation by exchanging
guanosine triphosphate (GTP) for guanosine diphosphate form (GDP), which allows it to
catalyze the electron transfer from NADPH to FAD (37). Also required for Nox
activation are the subunits, p47phox, and p67phox, which form a cytosolic complex
along with p40phox. Nox activation requires phosphorylation of p47phox by protein
kinase C (PKC) or tyrosine kinases (Src) which causes the cytosolic complex to
translocate to the membrane and bind the Nox catalytic subunit. Next, p67phox is
believed to be crucial in stimulating the electron transfer from NADPH (35, 36, 38).
Nox1 structure and function is very similar to that of Nox2. It contains a catalytic subunit
and p22Phox, forming a membrane bound complex as well as a cytosolic complex which,
in vascular tissue, must translocate to the membrane in order to induce enzyme activity
(35, 36, 38). Nox1 is most highly expressed in colon cells, and here, the cytosolic
complex is composed of Nox organizer 1 (NoxO1) and Nox activator 1 (NoxA1), which
are considered homologues of p47phox and p67phox respectively (34-36, 38). Unlike
p47phox, NoxO1 is constitutively active, increasing Nox1 activity and producing ROS.
While vascular smooth muscle Nox1 does contain NoxA1 in place of p67phox, it is
similar to Nox2 in that it contains p47phox rather than NoxO1, and requires
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phosphorylation for Nox activation (35, 36, 38). Figure 3 is a schematic of the various
Nox isoforms.
Nox4, while originally discovered in kidney cortex, is also present in human and rodent
vascular smooth muscle cells. Similarly to Nox1/2, it contains a membrane bound
complex consisting of the Nox catalytic subunit containing heme molecules and FAD,
and p22phox (35, 36). Nox4 is constitutively active without the presence of a cytosolic
complex, and its activity can be increased by binding of polymerase delta interacting
protein (PolDIP) 2 to p22phox (35, 36, 38). Nox5 on the other hand is not regulated by
additional subunits but contains an EF hand motif which acts as a Ca2+ binding domain,
and its activity is regulated by Ca2+ and CaM. Current evidence suggests that Nox1 and 2
are the isoforms most dominant in vascular smooth muscle, while Nox4 is expressed
primarily in endothelial cells and Nox5 expression has been confirmed in humans but not
rodents (36, 38). This study will therefore focus primarily on Nox1 and Nox2.
Nox-generated ROS may potentially facilitate myogenic constriction through regulation
of L-channels (10, 11) or moderate tone by regulating feedback mechanisms (5). These
feedback mechanisms generally involve depolarization-activated potassium channels
such as voltage gated potassium (KV) channels or large-conductance calcium activated
potassium (BKCa) channels which hyperpolarize cells, and lowering L-type Ca2+ channel
activity (10, 11). The well-established BK mediated negative feedback pathway on the
myogenic response requires BKCa channel activation via Ca2+ which is provided by
ryanodine receptors (RyR) located on the sarcoplasmic reticulum (SR). BKCa activity
then results in cell hyperpolarization, lowering L-channel activity, thereby attenuating
constriction (10, 11, 39). Although evidence exists that ROS can enhance the activity
both of L- and T-type Ca2+ channels (40, 41), the role of ROS in facilitating myogenic
tone has not been studied. This will be the focus of the present study.
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Figure 3: Nox isoforms found in vascular smooth muscle. Nox2 is considered the classic
prototype, while Nox 1, 4, and 5 are the other isoforms found in vascular myocytes. It
contains a membrane subunit bound to p22phox. Activation requires phosphorylation of
the cytosolic p47phox, which then translocates to the membrane, binding to p22phox,
causing binding of additional subunits p67phox and Rac. Similar to Nox2, Nox1
activation also requires phosphorylation of a cytosolic subunit (NoxO1 in colon or
p47phox in the vasculature) in order for cytosolic components to translocate to the
membrane. Nox4 activity is upregulated by polymerase delta interacting protein
(PolDIP)2 while Nox5 requires no additional subunits but is activated by Ca2+ binging to
its EF-hand motif.
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1.7 Goals and Hypothesis

Goal: to determine the role played by Nox enzymes in regulating myogenic tone in
cerebral arteries. Two specific aims are forwarded:
Specific aim 1: Determine the impact of Nox enzymes in the regulation of myogenic
tone.
We hypothesize that vascular smooth muscle Nox activity facilitates myogenic
constriction
Specific aim 2: Determine the mechanism linking Nox to myogenic tone.
We hypothesize that vascular smooth muscle Nox facilitates myogenic constriction by
inhibiting the T-type calcium channel, resulting in less BK channel activity, ultimately
inhibiting the feedback response on myogenic tone.

Figure 4: Proposed Mechanism of Nox regulation of the myogenic response. A
pressure sensor activates Nox, which inhibits CaV3.2, resulting in the reduction of Ca2+
sparks and subsequently reduced spontaneous transient outward current (STOC)
production from the BK channel and attenuated hyperpolarization, allowing L-type
channels to remain active, facilitating constriction.
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2 Methods
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2.1 Animals, Tissues, and cells
All procedures were approved by the University of Western Ontario Animal Care
Committee. Female Sprague-Dawley rats were euthanized via carbon dioxide
asphyxiation. The brain was gently removed and placed in ice-cold phosphate buffered
saline solution (PBS) (pH 7.4) containing (mM) 138 NaCl, 3 KCl, 10 Na2HPO4, 2
NaH2PO4, 5 glucose, 0.1 CaCl2, and 0.1 MgSO2. Third order posterior cerebral arteries
were dissected and cut into 2-3 mm segments and stored in PBS to be used the same-day
for pressure myography, PCR or enzymatic digestion.
Smooth muscle cells from rat arteries were enzymatically isolated as previously
described (11). Briefly, arterial segments were placed in an isolation medium (37°C, 10
min) containing (in mM): 60 NaCl, 80 Na-glutamate, 5 KCl, 2 MgCl2, 10 glucose and 10
HEPES with 1 mg/ml bovine serum albumin (pH 7.4). Vessels were then exposed to a
two-step digestion process that involved: 1) 12-15 min incubation in isolation medium
(37°C) containing 0.5 mg/ml papain and 1.5 mg/ml dithioerythritol; and 2) a 15 minutes
incubation in isolation medium containing 100 μM Ca2+, 0.7 mg/ml type F collagenase
and 0.4 mg/ml type H collagenase. Endothelial cells were similarly isolated using the
following digestion process: 1) a 30-min incubation in isolation medium (37ºC)
containing 1mg/mL BSA, 100 µM Ca2+, 1 mg/mL papain and 1 mg/mL dithioerythritol;
and 2) a 10-min incubation in isolation medium containing 1mg/mL BSA, 100 µM Ca2+,
0.9 mg/mL type-F collagenase, 0.6 mg/mL type-H collagenase, 5 mg/mL elastase and 1
mg/mL trypsin inhibitor. Following incubation, tissues were washed repeatedly with icecold isolation medium and triturated with a fire-polished pipette. Liberated cells were
manually picked with a suction pipette and stored in ice-cold isolation medium for use
the same day within ~5 hr.

2.2 Pressure Myography
Cerebral arteries were cannulated on a pressure arteriograph and superfused in 37oC
physiological saline solution (PSS) of pH 7.4 containing 119 mM NaCl, 4.7 mM KCl, 20
mM NaHCO3, 1.1 mM KH2PO4, 10 mM glucose, 1.6 mM CaCl2, and 1.2 mM MgSO4
while in a bath of Ca2+-free PSS (10). Artery diameter was measured using pressure
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myography techniques adapted from Abd El-Rahman et al (10). Briefly, arteries were
initially pressurized to a baseline of 15mmHg and given an initial equilibration period
(~25 min) in Ca2+-free PSS, followed by a second equilibration period (~10 min) in PSS
Ca2+, at which time vessel viability was tested by applying 55 mM external K+. Vessels
were considered viable if they constricted to ~50% of their initial baseline diameter in
response to K+ and returned to baseline following wash off in PSS. A pressure stimulus
of 60mmHg was applied until stable myogenic constriction was achieved (~5 minutes).
The vessel was returned to 15mmHg (10 min) and pressure increased to 60mmHg to
stimulate myogenic tone and held at this pressure for the duration of the experiment.
Diameter was measured after ten minutes at 60mmHg under control conditions with no
added reagents and under experimental conditions with the addition of pharmacological
inhibitors of ROS. Next, 200 nM nifedipine was applied (5 min), followed by 2 mM
EGTA to determine passive vessel diameter.

2.3 Quantitative real-time PCR
Quantitative real-time PCR was performed as previously described (10, 11). Briefly,
smooth muscle (~200) and endothelial cells (~100) were isolated from middle cerebral
arteries (n=4 arteries/group) and whole middle cerebral arteries (~2 from n=4
arteries/group) and placed in RNase- and DNase-free collection tubes. Total RNA was
extracted (RNeasy plus micro kit Qiagen, USA) and first-strand cDNA synthetized using
the Quantitect reverse transcription kit (Qiagen) according to instructions. For the
negative control groups, all components except the reverse transcriptase were included in
the reaction mixtures. Q-PCR was performed using the Kapa SYBR Fast Universal qPCR
Kit (Kapa Biosystems). Rat beta actin (ACTB) gene was utilized as the reference gene.
Control reactions and those containing cDNA from cerebral arteries were performed with
1 ng of template per reaction. Due to the very small quantities of RNA obtained from
isolated smooth muscle cells (~200 cells), the entire cDNA yield from each preparation
was used to assay the full set of test and housekeeping genes. The running protocol
included 45 cycles consisting of 95oC for 5 s, 55oC for 15 s, and 72oC for 10 s using an
Eppendorf Realplex 4 Mastercycler. PCR specificity was checked by dissociation curve
analysis. Assay validation was confirmed by testing serial dilutions of pooled template
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cDNAs suggesting a linear dynamic range of 0.1–100 ng template and yielded percent
efficiencies ranging from 85 to 108%. Template controls did not yield detectable
fluorescence. Expression of the Nox1 or Nox2 isoforms in cerebral arteries, endothelial,
or smooth muscle cells (n=4 arteries/ group) relative to control tissue was determined
using the relative expression software tool (REST) version 2.0.13.23. The primers for
RT-qPCR were as follows:
Nox1: TCAAACAGAAGAGAGCATGAGTG and CGAGGATCCACTTCCAAGAC
Nox2: TGTGTCGGAATCTCCTCTCC and CCGTGTGAAGTGCTATCATCC.
Actin: AGCACCCTGTGCTGCTCAC and GTACATGGCTGGGGTGTTG.

2.4 Proximity Ligation Assay
The Duolink in situ PLA kit was used for proximity ligation assay. Isolated vascular
smooth muscle cells were fixed in PBS containing 4% paraformaldhyde (15 min),
permeabilized in PBS containing 0.2% Tween20 (15 min). Cells were then washed with
PBS, blocked in Duolink blocking solution (1 h, 37°C), and incubated overnight (4°C)
with primary antibodies (rabbit anti-CaV3.2 and rabbit anti-Nox1) in Duolink antibody
diluent solution. Cells were labelled with Duolink PLA PLUS and MINUS probes (1 h,
37°C). The secondary antibodies of PLA PLUS and MINUS probes are attached to
synthetic oligonucleotides that hybridize when in close proximity (<40 nm). The
hybridized oligonucleotides were then ligated using Duolink ligase (30 min, 37oC) prior
to rolling circle amplification with Duolink polymerase (90 min, 37oC). The
amplification products extending from the oligonucleotide arm of the PLA probes were
detected using red fluorescent fluorophore-tagged, complementary oligonucleotide
sequences and a Leica-TSC SP8 confocal microscope.

2.5 Immunohistochemistry
Rat smooth muscle cells were enzymatically isolated as described above. Cells were
fixed in 4% paraformaldehyde for (15 min, room temperature) and permeabilized in PBS
containing 0.2% Tween20 for 15 min (room temperature). Cells were blocked using PBS
with 0.2% Tween20 and either 3% goat serum for Nox1, or 3% donkey serum for
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CaV3.2. Cells were incubated overnight at 4oC with primary antibodies against smooth
muscle CaV3.2 (1:100 dilution), and Nox1 (1:100 dilution), in working solution (0.2%
Tween20 in PBS with 2% donkey serum for CaV3.2 or 2% goat serum for Nox 1). Next,
cells were washed 4 times with PBS (5 min each, 22°C) and incubated with working PBS
solutions containing secondary antibodies (1h, 22°C). Following washes with PBS,
coverslips containing cells were mounted on glass slides containing mounting media and
stored (4°C). Controls were obtained by omitting the primary antibody. All reactions
involved the use of fluorophore-conjugated secondary antibodies (1:200 dilution): Alexa
Fluor 488-donkey anti-rabbit IgG, and Alexa Fluor 633-goat anti-rabbit IgG.
Immunolabelling was assessed using a Leica-TSC SP8 confocal microscope.

2.6 Chemical, drugs, and enzymes
The proximity ligation kit was purchased from Duolink. Buffer reagents, collagenases
(types F and H), dithioerythritol, paxilline, and mitoTEMPO were purchased from
Sigma-Aldrich. Papain and elastase were acquired from Worthington (USA) and
Calbiochem (USA), respectively. TEMPOL, ML-171, and apocynin were purchased from
Tocris, gp91-ds-tat was purchased from AnaSpec

2.7 Statistical Analysis
Data was expressed as means ± SE and n indicates the number of vessels or cells. For
vessel diameter measurements, data was also expressed in box-and-whisker plots. Oneway repeated measures ANOVA and paired t-tests with Bonferroni post-hoc tests were
performed as needed on vessels or cells to compare the effects of a given
condition/treatment on arterial diameter. (Sigmaplot, SPSS). P values ≤0.05 were
considered statistically significant.
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3 Results
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To begin assessing the effects of ROS on the blood vessel regulation, we ascertained the
impact of a general scavenger (TEMPOL) on myogenic tone by sequentially increasing
its concentration in the bath with rat cerebral arteries pressurized to 60 mmHg. Figure 5A
& 5B highlight the presence of a strong myogenic response yet the absence of a dilatory
or constrictor effect of TEMPOL as bath concentration rose from 10 to 100 µM. This
result was surprising but TEMPOL is known to have broad scavenging effects; we
rationalized that this superoxide dismutase mimetic might be simultaneously mitigating
ROS dependent mechanisms that are dilatory and constrictive. We repeated the preceding
experiment with target-selective agents, starting with MitoTEMPO, an agent that
selectively scavenges mitochondria-derived ROS. Analogous to the preceding findings,
MitoTEMPO, at concentrations ranging from 1 to 30 µM had no substantive impact on
myogenic tone development (Figure 5C & 5D).
The Nox family of enzymes are another rich source of ROS in the vasculature whose
activity has been linked to tone development (30-32, 40-42). To study their effect on
cerebral arterial myogenic tone development, myography experiments were performed in
the absence and presence of apocynin, a broad Nox inhibitor whose bath concentration
was sequentially increased from 30-300 µM. Working in endothelial intact and denuded
preparations, the latter condition induced by passing an air bubble down the lumen,
apocynin was observed to induce a transient concentration-dependent dilation over the
first 120 seconds followed by a slower constriction, with vessels returning modestly close
to baseline within ten minutes (Figure 6). While this data indicate a role for Nox in
facilitating the myogenic response, the isoform responsible for this effect remained
unclear. In this regard, real-time PCR analysis was performed focusing on Nox1 and
Nox2, the two dominant isoforms found in vascular tissue (Figure 7) (34-36, 38).
Consistent with the literature, we observed mRNA product for Nox1 and Nox2 in whole
cerebral arteries (34) (Figure 7A). Likewise, both isoforms were observed at the mRNA
level in freshly isolated smooth muscle and endothelial cells, roughly in equally
proportion. (Figure 7 B&C).
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Figure 5: Tissue and mitochondria specific ROS scavenging had no dilatory effect
on pressurized rat cerebral arteries. (A, D) Representative traces documenting the
effects of TEMPOL (A) or MitoTEMPO (D) on vessel diameter. (B, E) Summary data of
vessel responsiveness (n=6 vessels from 6 animals) to TEMPOL (B: 10-100 µM) or
MitoTEMPO (E: 1-30 µM). (C, F) maximum change in diameter from each concentration
of TEMPOL (C) or MitoTEMPO (F) relative to control.
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Figure 6: Nox inhibition initiates transient vasodilation. (A, D) Representative traces
documenting the effects of Nox inhibition (Apocynin) in endothelium intact (A) and
denuded (D) vessels. (B, E) Summary data of vessel responsiveness (n=6 vessels from 6
animals) to apocynin (30-300 µM) in endothelium intact (B) and denuded vessels (E). (C,
F) Maximum change in diameter from each concentration of apocynin in endothelium
intact (C) or denuded (F) vessels relative to control. * Indicates significant difference
from control; repeated measures ANOVA and Bonferroni post-hoc analysis.
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Figure 7: Nox1 and Nox2 mRNA are expressed in rat cerebral arterial tissue and
cells. (A) Real-time PCR data showing Nox1 and Nox2 mRNA expression in cerebral
arteries (n=4 arteries) relative to rat ileum and lung, respectively. (B-C) Nox1 and Nox2
mRNA expression in endothelial (n=~100 cells from 4 arteries) (B) and smooth muscle
(n=~200 cells from 4 arteries) (C) cells expressed relative to whole arterial tissue.
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Having confirmed the presence of Nox1 and Nox2 at the mRNA level, we next studied
their involvement in myogenic tone development. We performed pressure myography on
endothelium denuded vessels pressurized to 60mmHg and bathed in a Nox1-specific
(ML171, 1 to 30 µM) or Nox2 specific (gp91-dstat, 0.5 to 10 µM) inhibitor. The
application of ML-171 induced, in a concentration dependent manner a transient dilation
in rat cerebral arteries within the first two minutes, followed by a slower and incomplete
return to baseline (Figure 8A & 8B). In contrast, Nox2 inhibition by gp91-dstat had no
substantive impact on vessel diameter irrespective of the bath concentration (Figure 8C &
8D). Taken together, the preceding data support Nox1 rather than Nox2 aiding in the
development of myogenic tone in rat cerebral circulation.
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Figure 8: Nox1 but not Nox2 inhibition initiates vasodilation. (A, D) Representative
traces documenting the effects of Nox1 (ML-171) (A) or Nox2 inhibition (gp91-dstat)
(D). (B, E) Summary data of vessel responsiveness to ML-171 (n=9 vessels from 9
animals) (B; 1-30 µM)) or gp91-dstat (n=6 vessels from 6 animals) (E; 0.5-10 µM). (C,
F) maximum change in diameter from each concentration of ML-171 (C) or gp91-dstat
(F) relative to control. * Indicates significant difference from control; repeated-measures
ANOVA, Bonferroni post-hoc test.
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Given the modest dilation induced by Nox1 inhibition, we began to consider whether this
ROS generating system was facilitating myogenic constriction by inhibiting a key
feedback pathway. Further, we hypothesized that Nox might facilitate myogenic tone by
inhibiting CaV3.2, a T-type Ca2+ channel that triggers Ca2+ release from the RyR on
sarcoplasmic reticulum (SR), to activate BKCa and induce hyperpolarization (11, 39). If
correct, inhibitors that block the key mediating steps in this feedback pathway should
attenuate the dilatory response induced by Nox1 inhibition. Consistent with our working
hypothesis, we found that pre-treating cerebral arteries with paxilline (a BKCa inhibitor)
attenuated the dilation induced by ML-171, a change notable at the lower inhibitor
concentrations (Figure 9). A comparison of ML-171-induced dilation, in the presence vs.
the absence of paxilline revealed that BKCa blockade reduced the response by 30-40%
(Figure 9). The origins of the BKCa insensitive component are not currently known.
Nox1 regulation of myogenic constriction via direct interaction with CaV3.2 was tested
by repeating the preceding experiment in the presence of Ni2+, a selective CaV3.2
inhibitor. Our results show that ML-171 induced dilation was decidedly diminished, with
the attenuating effects of 30 M Ni2+ exceeding 50% (10 or 30µM ML-171) when
comparted to untreated tissues (Figure 10). Cumulatively, these data support our
hypothesis that Nox1 regulates myogenic tone in part by altering a key feedback pathway
involving CaV3.2 and BK channels.
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Figure 9: Large-conductance K+ (BK) channel blockade and ML171-induced
dilation. (A) Representative trace documenting the vasosmotor effects of ML-171 in the
presence of paxilline (1 µM). (B) Summary data of vessel responsiveness (time averaged,
n=6 vessels from 6 animals) to ML-171. Average diameter significantly increases at 10
µM and 30 µM concentrations. (C) Summary data highlighting diameter change to ML171 in the absence or presence of paxilline (1 µM) (n=6 vessels from 6 animals). *
Indicates significant difference from control; repeated measures ANOVA, Bonferroni
post-hoc analysis.
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Figure 10: Voltage-gated T-type Calcium Channel (CaV3.2) blockade and ML171induced dilation. (A) Representative trace documenting the vasosmotor effects of ML-171
in the presence of Ni2+ (50 µM). (B) Summary data of vessel responsiveness (time averaged,
n=6 vessels from 6 animals) to ML-171. (C) Summary data highlighting diameter change to
ML-171 in the absence or presence of Ni2+ (50 µM) (n=6 vessels from 6 animals). *
Indicates significant difference from control; repeated measures ANOVA with Bonferroni
post-hoc analysis.
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To strengthen the regulatory relationship between Nox1 and CaV3.2, it is important to
demonstrate that these two proteins are in close apposition. Immunohistochemistry was
first performed on isolated cerebral vascular smooth muscle to confirm Nox1 and CaV3.2
expression (Figure 11). Using fluorophore conjugated secondary antibodies, Nox1
appeared to be broadly distributed in the plasma membrane (Figure 11A), whereas
CaV3.2 labeling was decidedly more punctate (Figure 11C). Labeling was absent when
primary antibodies were omitted from the experimental protocol (Figure 11B & 11D).
Having confirmed expression, we performed the proximity ligation assay (PLA) to assess
whether CaV3.2 and Nox1 lie within 40 nm of one another (Figure 12). This assay entails
the use of primary antibodies for each protein of interest, which are subsequently bound
to selective secondary antibodies attached to synthetic oligonucleotide sequences which
hybridized when found in close enough proximity. The hybridized product then
undergoes rolling circle amplification via the use of a polymerase; the amplified product
is then detected using red fluorophore tagged oligonucleotide sequences. Red fluorescent
product was clearly observed at discrete points in the plasma membrane, consistent with
Nox1 and CaV3.2 lying in close apposition (Figure 12A-C). Controls were performed by
omitting one or both primary antibodies punctate labeling was absent; cell nuclei were
visualized with DAPI (Figure 12D-F).

30

Figure 11: Nox1 and CaV3.2 localization in rat cerebral vascular smooth muscle
cells. (A, C) Immunofluorescence images showing smooth muscle cell Nox1 (A) CaV3.2
(C). (B, D) Immunofluorescence images of control experiments containing only
secondary antibody.
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Figure 12: Nox1 and CaV3.2 are found in smooth muscle cells within 40 nm of one
another. (A-C) Proximity ligation assay with red dots indicating points of close
association of CaV3.2 and Nox1 (≤40 nm) with DAPI stained nuclei. (D-F) Control
images for proximity ligation assay using only a single primary antibody; either AntiNox1 (D), Anti-CaV3.2 (E), or using only the secondary antibody (F).
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4 Discussion
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This study determined a role for ROS, as generated by Nox, in facilitating myogenic
constriction in cerebral arteries. We began our investigation by applying a broad ROS
scavenger (TEMPOL) to pressurized cerebral arteries, a perturbation that had no effect on
vessel diameter (Figure 5A-5C). We next targeted two prominent ROS generating
systems; the first being the mitochondria. In this regard, the inhibitor MitoTEMPO was
without effect on vessel tone (Figure 5D-5F). In striking contrast, general Nox inhibition
(apocynin) attenuated but did not abolish myogenic constriction in a dose-dependent
manner (Figure 6). RT-PCR subsequently confirmed mRNA expression of Nox1 and
Nox2 in cerebral arterial smooth muscle cells (Figure 7). Building on these observations,
Nox-1 inhibition (ML-171) attenuated myogenic constriction while a Nox2 blocking
peptide was without effect (Figure 8). As the attenuation was modest, we subsequently
hypothesized that Nox1 was impinging upon a feedback response rather than enhancing
the main constrictor mechanism. Of particular note was the ability of extracellular Ca2+
influx via CaV3.2, to trigger BKCa-mediated hyperpolarization and dilation. Consistent
with this hypothesis, we showed that ML-171 induced dilation was attenuated in the
presence of paxilline or Ni2+, inhibitors of BK and CaV3.2, respectively (Figure 9, Figure
10). Lastly, proximity ligation assay confirmed a close association (~40 nm) between
CaV3.2 and Nox1 (Figure 12). Cumulatively, our results are the first to demonstrate that
Nox1 facilitates myogenic constriction by inhibiting a key feedback pathway tied to
CaV3.2 and the activation of BK channels. The latter hyperpolarizes smooth muscle,
diminishing the activity of L-type Ca2+ channels and consequently cytosolic [Ca2+]. Our
findings highlight the potential of Nox as a therapeutic target in disease states
(hypertension and diabetes) in which myogenic reactivity is compromised.

4.1 Background
Regulating the magnitude and distribution of blood flow is critical to vital organs and is
governed by the tuning of small resistance vessels. These vessels constrict and dilate in
response to various stimuli, one of the most important being intravascular pressure (1-4).
The myogenic response refers to the inherent ability of arteries to constrict to a rise in
intravascular pressure, a response that provides a base level of tone in key organs such as
brain, kidney and heart (5, 13, 42, 43). The myogenic response begins with the
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recruitment of a mechanosensor, whose downstream signaling pathway activates a nonselective cation channel and induces arterial depolarization (14). This electrical event
increases L-type Ca2+ channel activity; the subsequent influx of Ca2+ activates MLCK
increasing LC20 phosphorylation and crossbridge cycling (4, 5, 10, 13, 14). In addition to
this primary mechanism, pressure has been noted to inhibit MLCP via a RhoA-ROK
dependant mechanism and promote the formation of filamentous actin (5, 9, 15-20).
There are still aspects of myogenic constriction which require clarification, a major one
being the identity of the mechansensor. Recent work provides evidence that G-protein
coupled receptors may fill this role, including the AT1R (21-23). This receptor, when
activated by AngII binding or presumably pressure, induces constriction via a classic Gq
coupled pathway. This involves Gq activation of PLC, which subsequently produces IP3
and DAG. The former promotes Ca2+ release from the SR while the latter activates
protein kinase C (PKC), a serine/threonine kinase that phosphorylates a range of nonselective cation channels (30, 44). The AT1R is linked to additional downstream effectors
(21-23), one of interest being the Nox family of enzymes, whose primary function is to
produce ROS. While past studies have shown that Nox can target ion channels involved
in tone regulation (41, 45, 46), their effect on the myogenic response has not been
studied. It is this aspect of cell signaling that will be addressed in this thesis.

4.2 ROS Inhibition and the Myogenic Response
ROS and the deleterious impact of oxidative stress are most often considered in the
vascular context of diabetes, hypertension, and atherosclerosis (47-49). Their roles in
driving physiological processes are, however, poorly characterized although emerging
evidence suggests they may regulate ion channels involved in myogenic constriction (41,
45, 46). It was this aspect of tone development that we first considered by applying a
general ROS scavenger (TEMPOL) and monitoring its impact on pressurized vessels.
TEMPOL is a SOD mimetic containing a stable free radical which allows this compound
to convert superoxide to hydrogen peroxide which is then metabolized to water (50). Our
findings highlight that broad-based ROS scavenging had little effect on myogenic tone,
as evidenced by the lack of a notable change in vessel diameter in pressurized arteries
treated with TEMPOL (Figure 5A-5C). While such findings may suggest ROS do not
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play any role in regulating tone, they may alternatively suggest that scavenging ROS
from all sources in vascular tissue is too broad of a study, since different sources
simultaneously exert different effects on vessel diameter; some constrictor (32, 34-36, 40,
41) and some dilatory (35, 36, 38), removing all of these effects together would have no
net effect on tone. This highlights the importance of studying specific ROS generating
systems in relation to the myogenic response.
In vascular tissue, the two dominant systems of ROS generation are Nox and the
mitochondria (32, 34, 45), the latter of which we targeted with the ROS scavenger
mitoTEMPO, an agent comprised of the ROS scavenger TEMPO which has a similar
mechanism

of

action

to

TEMPOL,

combined

with

the

lipophilic

cation

triphenylphosphonium (TPP+) allowing it to target the mitochondria specifically (51).
Akin to TEMPOL, findings show that mitoTEMPO had no substantive effect on vessel
diameter when applied at concentrations that varied from 1-30 M. (Figure 5D-5F). This
observation contrasts the work of Chaplin and colleagues (45) whose findings suggest
that mitochondrial ROS generation upregulates L-type Ca2+ channel activity, leading to
vessel constriction (45). The notable difference between past and present findings may
reflect how the vessel was preconstricted (by pressure or agonist) and whether the
stimulus initiated ROS production (40, 45, 46). In light of these null findings, this study
shifted its attention to Nox.

4.3 Nox Inhibition Dilates Pressurized Arteries
The Nox family of enzymes are comprised of seven isoforms and in vascular tissue
Nox1, Nox2, Nox4, and Nox5 dominate (36, 38). All isoforms consist of a catalytic
membrane-bound complex comprised of six-transmembrane α-helices bound to two heme
groups and an FAD molecule. Nox1 and Nox2 are of particular importance to this study
as they localize to the plasma membrane (35, 36, 38, 52). When active, they are
comprised of three universal subunits (p22phox, p47phox and Rac) and one isoform
specific subunit NoxA1 (Nox1) and p67phox (Nox2) (35, 36). We began our
investigation of Nox-generated ROS by applying apocynin, a broad spectrum inhibitor
which retains reasonable target specificity when used at concentrations at or below 300
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µM (53-55). We intriguingly observed a concentration-dependent dilation of pressurized
vessels which displayed a transient and a sustained component (Figure 6). While the
mechanism of action has yet to be fully elucidated, it is possible that apocynin diminishes
Nox inhibition by interfering with the translocation of the cytosolic subunits to the
membrane (53-55). With these findings indicating a role for Nox-generated ROS in
myogenic tone development, we next sought to determine which isoform was specifically
involved. Quantitative real-time PCR analysis revealed that Nox1 and Nox2 mRNA were
expressed in cerebral arterial smooth muscle cells and as such, both would have to be
investigated at the functional level (34-36, 38) (Figure 7). In this regard, we first targeted
Nox1 by applying ML-171 to pressurized arteries. While this compound’s mechanism of
action is not well characterized, it has demonstrated some specificity for the Nox1
membrane subunit over any other isoforms or subunits (56-58). Our findings mirrored
those of apocynin, in that ML-171 induced a concentration-dependent dilation which
retained a transient and sustained component (Figure 8A-8C). In sharp contrast, the Nox2
inhibitor (gp91-dstat) which interferes with p47 binding to the Nox2 membrane complex
(57-59), had no notable impact on myogenic tone development (Figure 8D-8F).
Cumulatively, the preceding work indicates that Nox1 rather than Nox2 is the isoform
responsible for facilitating the myogenic response (Figure 8).
The preceding dilatory response to Nox inhibition was more modest and generally not
what was expected if ROS was targeting L-type Ca2+ channels, a key enabler of
myogenic constriction. (40, 42, 43, 45). This observation, lead us to consider whether
Nox-derived ROS was directed towards the modulation of a feedback pathway (10, 11,
32). In this regard, Nox1 is known to associate with caveolae (41, 44) as does CaV3.2, a
T-type Ca2+ channel (10, 11, 39). Previous work has shown that Ca2+ entry via CaV3.2
can trigger the cytosolic gate of RyR eliciting discrete events called Ca2+ sparks (10, 11,
39, 60, 61). These sparks in turn transiently activate BKCa producing spontaneous
transient outward currents (STOC) that hyperpolarize the cell, reduce L-type Ca2+
channel activity and attenuate constriction (10, 11, 32, 60, 61). Given the modest nature
of dilation observed with Nox1 inhibition, and published work showing that the CaV3.2
channels contain an oxidation site at histidine 191 (H191) (62), we rationalized that Nox1
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facilitates myogenic constriction by inhibiting Cav3.2 and moderating BKCa-mediated
feedback.

4.4 Nox1 Impacts BK-mediated Feedback
If Nox1 facilitates myogenic constriction by lowering BKCa-mediated feedback, then
ML-171 induced dilation should be attenuated when key components of this transduction
pathway are blocked. To test this hypothesis, cerebral arteries were pressurized to 60
mmHg and the dilatory response to ML-171 monitored in the absence and presence of the
BK channel inhibitor, paxilline. Paxilline (1 µM) markedly attenuated the dilation
induced by ML-171 at concentrations < 10µM. Upon increasing ML-171 concentration to
30 µM, paxilline attenuated the dilatory response by 30% (Figure 9). These data
generally support the idea that Nox1 affects BKCa-mediated feedback. To address
whether CaV3.2 is targeted by Nox1 in this feedback pathway, the preceding ML-171
experiments were repeated in the absence and presence of Ni2+ (50 µM). In the presence
of this CaV3.2 inhibitor, application of ML-171 at concentrations <10 µM was greatly
diminished, while the dilatory response of ≥10 µM ML-171 was attenuated by over 50%
(Figure 10). These findings support our view that Nox1 may indeed facilitate myogenic
constriction by moderating BKCa-mediated feedback via CaV3.2 inhibition. Note, recent
mechanistic work has shown that CaV3.2 is subject to inhibition via ROS oxidation at the
H191 residue (62). While Nox1 regulation of CaV3.2 is functionally important, this ROS
generating enzyme likely has other downstream targets as neither paxilline nor Ni 2+
completely blocked ML-171 induced dilation. This could be an important avenue for
future study but is beyond the scope of the present work.

4.5 Nox1 Localization with CaV3.2
For Nox1-generated ROS to interact with CaV3.2, it is clear that the two proteins must
reside in close apposition with one another. To visualize this close association, we
undertook a set of immunolabeling experiments. First, traditional immunohistochemistry
approaches were used to visualize the distribution pattern of Nox1 and CaV3.2 in vascular
smooth muscle (Figure 11). Confocal microscopy employing fluorophore-conjugated
secondary antibodies confirmed that Nox1 was broadly distributed along vascular smooth
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muscle cells while CaV3.2 was expressed in more discreet regions along the plasma
membrane, consistent with published work (10, 11, 34-38, 41) (Figure 11). A more broad
distribution of Nox1 in smooth muscle cells supports the idea that it has additional
downstream targets, which would explain why CaV3.2 inhibition did not entirely abolish
ML-171-induced dilation. Subsequently, PLA, a technology that extends traditional
immunoassays, was employed and synthetic oligonucleotide probes were used which
hybridize when found ≤40 nm to both Nox1 and CaV3.2. Hybridized products were
amplified

with

polymerase

and

visualized

with

red

fluorophore

conjugated

oligonucleotides, appearing as red spots at discreet points along isolated cells. (Figure 12)
These results align with previous work which show that both Nox1 (34-36, 38, 45, 46),
and CaV3.2 (10, 11, 39, 41) are found at plasma membrane caveolae, thus providing
evidence that Nox-generated ROS are able to reach and interact with CaV3.2 (Figure 13).
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Figure 13: Proposed Mechanism of Action
Constriction. Nox1 facilitates constriction by
feedback. Intravascular pressure activates Nox1,
lowering Ca2+ spark production and subsequent
thereby increasing the open-probability of L-type
Ca2+ required for constriction.

of Nox1 Regulation of Myogenic
moderating BKCa-induced negative
which subsequently inhibits CaV3.2,
hyperpolarizing STOCs from BKCa,
Ca2+ channels, the primary source of
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4.6 Limitations
While apocynin is widely viewed as a Nox inhibitor (53-55), it has been suggested that in
vascular smooth muscle it is a more potent ROS scavenger (63). This was an important
consideration as it could indicate that the observed apocynin effects might be due to
broad-based ROS scavenging rather than specific inhibition of Nox. Two steps were
taken to address this concern, the first being that apocynin concentrations did not exceed
300 µM, the point at which broader ROS scavenging effects are typically observed (63).
Second, we examined the effects of a broad-based ROS scavenger (TEMPOL) and found
that it had no substantive effect on myogenic tone development. This lies is in contrast to
apocynin application which elicited a dose dependent vasodilation. Target specificity has
also been a concern with ML-171, as previous work suggests that in addition to inhibiting
Nox1, it can target Nox2 (56-58). Two important measures were again taken to address
the compound’s specificity. First, ML-171 concentrations were kept ≤30 µM, a dose that
has limited impact on the Nox2 ROS generating system (56). Second, we examined the
effects of a Nox2 peptide inhibitor (gp91-dstat) and found no notable effect on myogenic
tone development. This functional phenotype is different from the concentrationdependent dilation induced by ML-171.
It should be clearly noted that this study specifically focused on Nox1 and Nox2 as these
ROS generating enzymes are present in the plasma membrane (35, 36, 38, 52) and
regulate Ca2+ channels involved in myogenic tone development (4, 10, 11, 39). Nox4 and
Nox5 on the other hand, do not adhere to this criteria, thus they are unlikely to impact ion
channels involved in vasomotor control (34-36, 38). Further to this point, there is no
evidence that Nox4 can modulate tone, except perhaps in disease states that acutely affect
brain blood flow (64). The physiological importance of Nox5 is difficult to assess in
rodent, as expression is sparse in vascular smooth muscle (35, 36).

4.7 Future Directions
To strengthen the relationship between Nox1, CaV3.2, and BKCa-mediated feedback, it
would be valuable to directly assess the effect of Nox1 inhibition on these key ion
channels by undertaking patch-clamp electrophysiology. Of particular note would be
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measurements of Ca2+ sparks and STOCs, in the presence and absence of ML-171, to
directly link Nox1 regulation to CaV3.2 or BKCa activity. There is also considerable value
in directly measuring Nox expression and activity using western blot techniques or ROS
sensitive dyes, respectively. Lastly, the dilatory phenotypes induced by pharmacological
Nox inhibitors in pressurized vessels should be verified in knock-out (KO) animal
models. It would be of particularly value to compare the myogenic response in resistance
arteries of Nox1 knockout animals to wild-type controls.
To build upon the present study, two critical mechanisms regarding the ability of Nox to
regulate myogenic tone may be further studied. First it is important to mechanistically
resolve the component of ML-171-induced dilation insensitive to paxilline or Ni2+. While
data is limited, Nox1-generated ROS may be targeting more than one feedback
mechanism (61). One mechanism of note involves the multiple KV channels that are
expressed in vascular smooth muscle cells (61). Second, the mechanism by which Nox1
can affect CaV3.2 should be determined. Previous work suggests that Nox-derived ROS
affects vascular Voltage-gated Ca2+ channels (VGCC) via a mechanism dependent on
Protein Kinase C (PKC) (65-70). ROS has been shown to activate PKC (68) and
consequently neighboring L-type Ca2+ channels (66-70). Pressure myography,
electrophysiology and immunofluorescence techniques may be applied to determine if a
similar mechanism links Nox1 and CaV3.2. Alternatively, Orestes and colleagues have
shown that ROS may directly oxidize the H191 site of CaV3.2 resulting in channel
inhibition (62). While intriguing, these findings are currently limited to neural CaV3.2
(62) and replicating this work in vascular tissue would be of value to the myogenic field
of study.

4.8 Summary
The findings of this study support the idea that Nox1-generated ROS plays a role in
facilitating myogenic constriction in cerebral resistance arteries via inhibition of BKCainduced negative feedback. We provide evidence that Nox1 is in close proximity to, and
suppresses CaV3.2 channel activity, reducing BKCa-induced hyperpolarization, thereby
increasing the open-probability of L-type Ca2+ channels, the main source of Ca2+ required
for constriction. This study is the first to provide evidence that Nox1-generated ROS
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facilitates constriction by inhibiting a feedback pathway rather than by enhancing a main
constrictor mechanism. This newly proposed mechanism of tone regulation has potential
to contribute to combating the excessive constriction often observed in vascular disease
states such as hypertension or diabetes.
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